Go Pro
→ China is not hedging. It's escaping. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$255.41
$246.03
$175.19
▼
$282.15
$15.93B0.39514,876 shs325,549 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$84.48
$75.69
$45.40
▼
$93.42
$16.51B0.962.08 million shs2.15 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$31.25
$27.31
$21.00
▼
$35.43
$19.49B0.832.04 million shs3.51 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+4.71%-5.56%+7.01%+33.38%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+5.48%-1.64%+30.61%+81.37%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+114.35%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+8.24%+7.76%+19.37%+45.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$255.41
$246.03
$175.19
▼
$282.15
$15.93B0.39514,876 shs325,549 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$84.48
$75.69
$45.40
▼
$93.42
$16.51B0.962.08 million shs2.15 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$14.49
$14.42
$5.51
▼
$14.50
$4.55B0.482.62 million shs5.29 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$31.25
$27.31
$21.00
▼
$35.43
$19.49B0.832.04 million shs3.51 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+4.71%-5.56%+7.01%+33.38%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+5.48%-1.64%+30.61%+81.37%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%0.00%0.00%0.00%+114.35%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+8.24%+7.76%+19.37%+45.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.06
Buy$296.1215.94% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.82
Moderate Buy$97.3315.21% Upside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.00
Hold$14.560.50% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5026.40% Upside

Current Analyst Ratings Breakdown

Latest FOLD, GMAB, BBIO, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $42.00
7/28/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
7/23/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$256.00 ➝ $275.00
7/22/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
New Street Research logo
New Street Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$43.00
7/22/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$32.00 ➝ $43.00
7/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$82.00 ➝ $93.00
7/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C)
7/13/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$110.00 ➝ $120.00
7/7/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$275.00 ➝ $280.00
7/2/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$38.00 ➝ $40.00
6/23/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$38.00
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.56N/AN/A($2.97) per share-86.00
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M32.89N/AN/A($10.77) per share-7.84
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$634.21M7.17$0.06 per share234.67$0.87 per share16.66
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.24$1.61 per share19.41$9.10 per share3.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6729.4622.15N/A57.87%N/A-8.37%8/13/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A1,206.86N/A-124.42%N/A-65.81%8/10/2026 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2724.6119.901.9519.08%14.89%7.73%N/A

Latest FOLD, GMAB, BBIO, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71N/AN/AN/A$376.75 millionN/A
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756N/AN/AN/A$220.91 millionN/A
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
1.43
2.84
1.88
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.20%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480314.00 million307.09 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.53 million613.93 millionOptionable

Recent News About These Companies

Legacy Wealth Asset Management LLC Grows Stake in Genmab A/S Sponsored ADR $GMAB
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legacy-wealth-asset-management-llc-grows-stake-in-genmab-as-sponsored-adr-gmab-2026-08-10/
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $42.00
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951491
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB), Irhythm Technologies (IRTC) and Editas Medicine (EDIT)
August 9 at 12:24 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GMAB-Q/pressreleases/3739702/analysts-have-conflicting-sentiments-on-these-healthcare-companies-genmab-gmab-irhythm-technologies-irtc-and-editas-medicine-edit/
Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook
August 7 at 5:35 PM  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/genmab-stock-rises-4-4-164350819.html
Guggenheim Boosts Genmab A/S (NASDAQ:GMAB) Price Target to $42.00
August 7 at 1:23 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/guggenheim-boosts-genmab-as-nasdaqgmab-price-target-to-4200-2026-08-07/
Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript
August 7 at 9:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4933005-genmab-a-s-gmab-q2-2026-earnings-call-transcript
Genmab (GMAB) Q2 2026 Earnings Call Transcript
August 7 at 1:38 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/genmab-gmab-q2-2026-earnings-011217098.html
Genmab A/S (NASDAQ:GMAB) Issues Earnings Results, Beats Expectations By $0.12 EPS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genmab-as-nasdaqgmab-issues-earnings-results-beats-expectations-by-012-eps-2026-08-06/
Genmab A/S Q2 Earnings Call Highlights
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genmab-as-q2-earnings-call-highlights-2026-08-06/
Genmab A/S 2026 Q2 - Results - Earnings Call Presentation
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932184-genmab-a-s-2026-q2-results-earnings-call-presentation
Quantinno Capital Management LP Grows Position in Genmab A/S Sponsored ADR $GMAB
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-grows-position-in-genmab-as-sponsored-adr-gmab-2026-08-06/
Sanctuary Advisors LLC Decreases Holdings in Genmab A/S Sponsored ADR $GMAB
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sanctuary-advisors-llc-decreases-holdings-in-genmab-as-sponsored-adr-gmab-2026-08-01/
Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMAB
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-avidity-partners-management-lp-cuts-stock-holdings-in-genmab-as-sponsored-adr-gmab-2026-08-01/
Genmab A/S (GMAB) Projected to Announce Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genmab-as-gmab-projected-to-announce-earnings-on-thursday-2026-07-30/
SummitTX Capital L.P. Makes New Investment in Genmab A/S Sponsored ADR $GMAB
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-summittx-capital-lp-makes-new-investment-in-genmab-as-sponsored-adr-gmab-2026-07-29/
Genmab's H1 Preview: Darzalex Beats The Sales Outlook
July 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926101-genmabs-h1-preview-darzalex-beats-the-sales-outlook
Genmab (GMAB) Receives a Hold from Morgan Stanley
July 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GMAB/pressreleases/3447778/genmab-gmab-receives-a-hold-from-morgan-stanley/
Genmab A/S Sponsored ADR $GMAB Shares Bought by Renaissance Technologies LLC
July 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-genmab-as-sponsored-adr-gmab-shares-bought-by-renaissance-technologies-llc-2026-07-26/
First Trust Advisors LP Purchases 1,126,069 Shares of Genmab A/S Sponsored ADR $GMAB
July 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-trust-advisors-lp-purchases-1126069-shares-of-genmab-as-sponsored-adr-gmab-2026-07-26/
Genmab: Multiple Late-Stage Readouts Ahead
July 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4924223-genmab-multiple-late-stage-readouts-ahead
Genmab A/S (NASDAQ:GMAB) Raised to "Buy" at TD Cowen
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/genmab-as-nasdaqgmab-raised-to-buy-at-td-cowen-2026-07-22/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
A gloved hand holds a white capsule pill in a pharmaceutical laboratory setting.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
By Jeffrey Neal Johnson | July 13, 2026
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$255.41 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$255.93 +0.52 (+0.20%)
As of 08/7/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$84.48 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$85.14 +0.66 (+0.78%)
As of 06:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$31.25 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$30.40 -0.85 (-2.72%)
As of 06:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas